Lekh Dahal

Senior Lecturer

University of Liverpool

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Lekh Dahal is a Senior Lecturer at the University of Liverpool, UK. His research primarily focuses on the STING pathway in cancer immunology, the regulation of antibody-mediated target cell depletion, and the implications of various immune mechanisms in malignancies. Recent publications include studies on HIF activation in tumor targeting, TGFβ2's role in checkpoint inhibition for melanoma, and advancements in interferon therapy for myeloid malignancies.

Articles (10)

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (4)

Yury Bogdanov

Lecturer in Transgenic Technologies

University of Southampton

UNITED KINGDOM

View details

Andrejs Braun

Reader in Genome Regulation

Queen Mary University of London Barts and The London School of Medicine and Dentistry

UNITED KINGDOM

View details

Alexander Simpson

University College London

UNITED KINGDOM

View details

Professor Jonathan C Strefford

Professor of Molecular Oncology

University of Southampton

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Lekh Dahal

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Differential Regulation of the STING Pathway in Human Papillomavirus-Positive and -Negative Head and Neck Cancers.

FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.

Worked to the bone: antibody-based conditioning as the future of transplant biology.

HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy.

TGFβ2 Induces the Soluble Isoform of CTLA-4 - Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma.

Recent Progress in Interferon Therapy for Myeloid Malignancies.

Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia.

STINGing Viral Tumors: What We Know from Head and Neck Cancers.

Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review.

Old Dog, New Trick: Type I IFN-Based Treatment for Acute Myeloid Leukemia.

Collaborators (4)

Yury Bogdanov

Andrejs Braun

Alexander Simpson

Professor Jonathan C Strefford

Make your next move.